177Lu-PSMA-617, an investigational radioligand therapy, showed stronger clinical activity than cabazitaxel in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel.
A 4-step quality improvement intervention increased compliance with American Urological Association guidelines for periprocedural antibacterial prophylaxis for high-risk patients receiving cystoscopy.
